title: Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases.
abstract: OBJECTIVE
  To analyze the significance of different clinical factors for prognostic prediction in diffuse large B-cell lymphoma (DLBCL) patients.
  
  
  METHODS
  Two hundred and twenty-seven DLBCL patients were retrospectively reviewed. Patients were managed with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen or rituximab plus the CHOP (RCHOP) regimen.
  
  
  RESULTS
  Lactate dehydrogenase (LDH), β2- microglobulin (β2-M), B symptoms, Ann Arbor stage and genetic subtypes were statistically relevant in predicting the prognosis of the overall survival (OS). In the CHOP group, the OS in patients with germinal center B-cell- like (GCB)(76.2%) was significantly higher than that of the non-GCB group (51.9%, P=0.032). With RCHOP management, there was no statistical difference in OS between the GCB (88.4%) and non-GCB groups (81.9%, P=0.288).
  
  
  CONCLUSIONS
  Elevated LDH and β2-M levels, positive B symptoms, Ann Arbor stage III/IV, and primary nodal lymphoma indicate an unfavorable prognosis of DLBCL patients. Patients with GCB-like DLBCL have a better prognosis than those with non-GCB when treated with the CHOP regimen. The RCHOP treatment with the addition of rituximab can improve the prognosis of patients with DLBCL.
authors.affiliation: Department of Hematology, Bone Marrow Transplant Center, the First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China.
authors.forename: De
authors.initials: D
authors.lastname: Zhou
authors.forename: Wan-Zhuo
authors.initials: WZ
authors.lastname: Xie
authors.forename: Ke-Yue
authors.initials: KY
authors.lastname: Hu
authors.forename: Wei-Jia
authors.initials: WJ
authors.lastname: Huang
authors.forename: Guo-Qing
authors.initials: GQ
authors.lastname: Wei
authors.forename: Jing-Song
authors.initials: JS
authors.lastname: He
authors.forename: Ji-Min
authors.initials: JM
authors.lastname: Shi
authors.forename: Yi
authors.initials: Y
authors.lastname: Luo
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Jing-Jing
authors.initials: JJ
authors.lastname: Zhu
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
authors.forename: Mao-Fang
authors.initials: MF
authors.lastname: Lin
authors.forename: Xiu-Jin
authors.initials: XJ
authors.lastname: Ye
authors.forename: Zhen
authors.initials: Z
authors.lastname: Cai
authors.forename: He
authors.initials: H
authors.lastname: Huang
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D018858:Germinal Center / Q000473:pathology; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000188:drug therapy / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D000069283:Rituximab; D013534:Survival; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use; D001613:beta 2-Microglobulin / Q000097:blood*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D001613:beta 2-Microglobulin; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D007770:L-Lactate Dehydrogenase; D011241:Prednisone